Historical ci News Stories
Cigna Shares Slip Amid Guidance, Dividend Boost Q1
Cigna (CI) saw a recent share decline despite raising its dividend and reaffirming 2026 guidance. Key developments this week: a near 2.7% intraday drop, a higher quarterly dividend, insider sales, a modest analyst price-target trim, and AM Best credit affirmation. These events create mixed signals for investors ahead of the company’s upcoming earnings.
Cigna (CI) Faces Medicare-Rate Freeze; Stock Dips.
Cigna’s shares fell after a CMS Medicare Advantage rate proposal sent insurer stocks lower. Cigna’s limited MA exposure and Evernorth diversification helped limit the hit; analysts retain constructive 12‑month targets.
Cigna Q1 Guidance Dip: PBM Shift and ACA Cuts 2026
Cigna's late-February gains mask deeper headwinds: weaker-than-expected 2026 guidance, Evernorth's PBM model transition, and ACA/Medicaid funding changes that pressure enrollment and margins.
Cigna Drops After Geopolitics, Q4 Beats & Hike Up
Cigna (CI) posted a strong Q4 beat with EPS of $8.08, $72.5B revenue and a 3.3% dividend increase, yet its stock slipped in mid-February amid risk‑off selling tied to geopolitical headlines and lower-than-average trading volume. Analysts remain constructive with raised EPS outlooks and above‑market price targets, while competitive pressure from Amazon Pharmacy and PBM dynamics merit close monitoring.
Cigna Cuts 2,000 Jobs; Earnings & PBM Shift Impact
Cigna's recent announcement of roughly 2,000 layoffs, its Q4 2025 results led by Evernorth, and a strategic shift toward a rebate-free PBM model have immediate financial and operational implications for CI stock. This article breaks down the near-term cost-savings, earnings drivers, regulatory touchpoints and what investors should watch next.
Cigna Q4 Beat; Evernorth Growth and Dividend Lift!
Cigna reported strong full-year 2025 results driven by Evernorth growth, raised its quarterly dividend and issued a confident 2026 outlook. While the stock saw modest post-earnings gains, sector headwinds—most notably collapsing ACA enrollment for some peers—remain a watch item for investors.